S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT2B7 in the elimination of naproxen

British Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2005, Pages 423-433

  Bowalgaha, Kushari ^a   Elliot, David J ^a   Mackenzie, Peter I ^a   Knights, Kathleen M ^a   Swedmark, Stellen ^b   Miners, John O ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Desmethylnaproxen; Human drug glucuronidation; S naproxen; UDP glucuronosyltransferase; UGT2B7

Indexed keywords

FLUCONAZOLE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; NAPROXEN; NORNAPROXEN; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; NAPROXEN;

EID: 26444551640     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02446.x     Document Type: Article

References (29)

1. Prescription cost analysis data. Drugs used in rheumatic diseases and gout, http://www.publications.doh.gov.uk/ prescriptionstatistics/
2. Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. J Pharm Sci 1980; 69: 1254-7.
3. Vree TB, van den Biggelaar-Martea M, Verwey-Vvan Wissen CPWGM, Vree ML, Guelen PJM. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effects Cimetidine Br J Clin Pharmacol 1993;35:467-72.
4. Runkel R, Chaplin M, Sevelius H, Ortega E, Segre E. Pharmacokinetics of naproxen overdoses. Clin Pharmacol Ther 1976; 24: 269-77.
5. Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P450 1A2 and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51: 1003-8.
6. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch I, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Roy Chowdhury J, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW. The UDP-glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-69.
7. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: Application of in vitro and in silico modelling approaches. Ann Rev Pharmacol Toxicol 2004; 44: 1-25.
8. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression and disease. Ann Rev Pharmacol Toxicol 2000; 40: 581-616.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement by the Folin phenol reagent. 1951; 193: 265-75.
10. Boase S, Miners JO. In vitro - in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 2002; 54: 493-503.
11. Uchaipichat V, Mackenzie PI, Guo X-H, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human UDP-glucuronosyltransferases. Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Disp 2004; 32: 413-23.
12. Dehal SS, Gagne PV, Crespi CL, Patten CJ. Characterization of a probe substrate and an inhibitor of UDP glucuronosyltransferase (UGT) 1A4 activity in human liver microsomes (HLM) and cDNA-expressed UGT-enzymes. http://www.bdbiosciences.com/ discovery_labware/gentest/products/pdf/ 1A4_AAPS_S01 T056R
13. Houston JB, Kenworthy KE. In vitro - in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Disp 2000; 28: 246-54.
14. Cornish-Bowden A. Control of enzyme activity. In Fundamentals of Enzyme Kinetics, London: Portland Press 1995; 203-16.
15. McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000; 49: 453-61.
16. Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E. Naproxen-probenecid interaction. Clin Pharmacol Ther 1978; 24: 706-13.
17. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence of atypical glucuronidation kinetics by UGT2B7. Drug Metab Disp 2003; 31: 1086-9.
18. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzed estradiol 3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Disp 2002; 30: 1266-73.
19. Soars MG, Ring BJ, Wrighton SA. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferase. Drug Metab Disp 2003; 31: 762-7.
20. Jin C-J, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate glucuronosyltransferase glucuronidating carboxylic acid containing drugs. J Pharmacol Exp Ther 1993; 264: 475-9.
21. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, xenobiotics and androgens by human UGT2B7(Y268) and UGT2B7(H268). Drug Metab Disp 1998; 26: 73-7.
22. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Belanger A. 3′-Azido-3′-deoxythymidine is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Disp 2000; 28: 497-502.
23. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 1997; 57: 284-9.
24. Yue Q, von Bahr C, Odar-Cederlof I, Sawe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol 1990; 66: 221-6.
25. Sahai J, Gallicano K, Pakuts A, Cameron WD. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169: 1103-7.
26. Bhasker CR, McKinnon W, Stone A, Lo ACT, Kubota T, Ishizaki T, Miners JO. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-85.
27. Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E. Nonlinear plasma level response to high doses of naproxen. Clin Pharmacol Ther 1974; 20: 261-6.
28. Tsoutsikos P, Miners JO, Stapleton A, Thomas T, Sallustio BC, Knights KM. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 2004; 67: 191-9.
29. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001; 52: 605-9.